Tomlins et al. reply

Scott A. Tomlins (), Bharathi Laxman (), Saravana M. Dhanasekaran (), Beth E. Helgeson (), Xuhong Cao (), David S. Morris, Anjana Menon (), Xiaojun Jing (), Qi Cao (), Bo Han (), Jindan Yu (), Lei Wang (), James E. Montie, Mark A. Rubin, Kenneth J. Pienta, Diane Roulston (), Rajal B. Shah (), Sooryanarayana Varambally (), Rohit Mehra () and Arul M. Chinnaiyan ()
Additional contact information
Scott A. Tomlins: Michigan Center for Translational Pathology, University of Michigan Medical School
Bharathi Laxman: Michigan Center for Translational Pathology, University of Michigan Medical School
Saravana M. Dhanasekaran: Michigan Center for Translational Pathology, University of Michigan Medical School
Beth E. Helgeson: Michigan Center for Translational Pathology, University of Michigan Medical School
Xuhong Cao: Michigan Center for Translational Pathology, University of Michigan Medical School
David S. Morris: University of Michigan Medical School
Anjana Menon: Michigan Center for Translational Pathology, University of Michigan Medical School
Xiaojun Jing: Michigan Center for Translational Pathology, University of Michigan Medical School
Qi Cao: Michigan Center for Translational Pathology, University of Michigan Medical School
Bo Han: Michigan Center for Translational Pathology, University of Michigan Medical School
Jindan Yu: Michigan Center for Translational Pathology, University of Michigan Medical School
Lei Wang: Michigan Center for Translational Pathology, University of Michigan Medical School
James E. Montie: University of Michigan Medical School
Mark A. Rubin: Brigham and Women’s Hospital, Harvard Medical School
Kenneth J. Pienta: University of Michigan Medical School
Diane Roulston: Michigan Center for Translational Pathology, University of Michigan Medical School
Rajal B. Shah: Michigan Center for Translational Pathology, University of Michigan Medical School
Sooryanarayana Varambally: Michigan Center for Translational Pathology, University of Michigan Medical School
Rohit Mehra: Michigan Center for Translational Pathology, University of Michigan Medical School
Arul M. Chinnaiyan: Michigan Center for Translational Pathology, University of Michigan Medical School

Nature, 2009, vol. 457, issue 7231, E2-E3

Abstract: Abstract Replying to: Carver, B. S. et al. Nature 457, 10.1038/nature07738 (2009) Carver et al. 1 question our recent report that mice expressing ETV1 under the control of the probasin promoter (ARR2Pb) develop mouse prostatic intraepithelial neoplasia (mPIN)2. They report the generation of transgenic ARR2Pb-ERG mice with no phenotypic differences from control mice. They propose that this demonstrates that ETS genetic rearrangements do not initiate prostate tumorigenesis and use data from human prostate cancer studies to propose that ETS rearrangements are associated with progression from PIN to prostate cancer. Although we and others have shown that ARR2Pb-ETV1 and ARR2Pb-ERG mice develop mPIN, we have consistently proposed that in human prostate cancer development, ETS rearrangements mediate the transition from PIN to cancer.

Date: 2009
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature07739 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:457:y:2009:i:7231:d:10.1038_nature07739

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07739

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().